Novel therapeutic strategies in Parkinson's disease

European Journal of Clinical Pharmacology

Volumn 66, Issue 2, 2010, Pages 119-125

  Klivenyi, Peter ^a   Vecsei, Laszlo ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; APLINDORE; CREATINE; DOPAMINE RECEPTOR STIMULATING AGENT; ETIRACETAM; FIPAMEZOLE; FOLIC ACID; INOSINE; ISRADIPINE; KYNURENINE; LEVODOPA; METHYLPHENIDATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEU 120; NICOTINE; PLACEBO; SAFINAMIDE; SCH 420814; SYN 115; UBIDECARENONE; UNCLASSIFIED DRUG; V 1512; VITAMIN D;

ADD ON THERAPY; BRAIN LEVEL; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSKINESIA; FOLIC ACID DEFICIENCY; GAIT; HUMAN; LOW DRUG DOSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SMOKING; SOMNOLENCE; VITAMIN BLOOD LEVEL; VITAMIN INTAKE;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DOPAMINE AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 76949084998     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0742-4     Document Type: Review

References (48)

1. ER Dorsey R Constantinescu JP Thompson KM Biglan RG Holloway K Kieburtz FJ Marshall BM Ravina G Schifitto A Siderowf CM Tanner 2007 Projected number of people with Parkinson's disease in the most populous nations, 2005 through 2030 Neurology 30 384 386 10.1212/01.wnl.0000247740.47667.03 (Pubitemid 46184217)
2. W Poewe 2009 Treatments for Parkinson's disease-past achievements and current clinical needs Neurology 72 7 Suppl S65 S73 10.1212/WNL.0b013e31819908ce 1:CAS:528:DC%2BD1MXhslygsLo%3D 19221317
3. B Kandinov N Giladi AD Korczyn 2009 Smoking and tea consumption delay onset of Parkinson's disease Parkinsonism Relat Disord 15 41 46 10.1016/j.parkreldis.2008.02.011 18434232
4. MR Picciotto M Zoli 2008 Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease Front Biosci 13 492 504 10.2741/2695 1:CAS:528:DC%2BD1cXhs1Chtr8%3D 17981563 (Pubitemid 351599760)
5. DP Hong AL Fink VN Uversky 2009 Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochim Biophys Acta 1794 282 290 1:CAS:528:DC%2BD1MXktlCgtw%3D%3D 19013262
6. G Villafane P Cesaro A Rialland S Baloul S Azimi C Bourdet J Le Houezec I Macquin-Mavier P Maison 2007 Chronic high dose transdermal nicotine in Parkinson's disease: an open trial Eur J Neurol 14 1313 1316 10.1111/j.1468-1331.2007.01949.x 1:STN:280:DC%2BD2snptFGjsg%3D%3D 17941858 (Pubitemid 350135288)
7. A Vieregge M Sieberer H Jacobs JM Hagenah P Vieregge 2001 Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study Neurology 57 1032 1035 1:CAS:528:DC%2BD3MXnsVCnsbo%3D 11571330
8. G Ebersbach M Stöck J Müller G Wenning J Wissel W Poewe 1999 Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration Mov Disord 14 1011 1013 10.1002/1531- 8257(199911)14:6<1011::AID-MDS1016>3.0.CO;2-F 1:STN:280: DC%2BD3c%2FkvFeksQ%3D%3D 10584678
9. T Bordia C Campos L Huang M Quik 2008 Continuous and intermittent nicotine treatment reduces L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease J Pharmacol Exp Ther 327 239 247 10.1124/jpet.108.140897 1:CAS:528:DC%2BD1cXht1amsLfI 18650244
10. M Quik K O'Leary CM Tanner 2008 Nicotine and Parkinson's disease: implications for therapy Mov Disord 23 1641 1652 10.1002/mds.21900 18683238
11. P Klivenyi RT Matthews M Wermer L Yang U MacGarvey DA Becker R Natero MF Beal 1998 Azulenyl nitrone spin traps protect against MPTP neurotoxicity Exp Neurol 152 163 166 10.1006/exnr.1998.6824 1:CAS:528:DyaK1cXlsFKrsrY%3D 9682023 (Pubitemid 28366977)
12. Ascherio A, LeWitt PA, Watts A, Kieburtz K, Rudolph A, Schwid SR, et al. on behalf of the PSG DATA TOP investigators (2006) CSF as well as serum urate are predictors of Parkinson's disease progression. Movement Disorders Society International Congress on Parkinson's Disease and Movement Disorders, Kyoto, Japan, 2006 LB-2
13. MA Schwarzschild SR Schwid K Marek A Watts AE Lang D Oakes I Shoulson A Ascherio C Hyson E Gorbold A Rudolph K Kieburtz S Fahn L Gauger C Goetz J Seibyl M Forrest J Ondrasik Parkinson Study Group PRECEPT Investigators 2008 Serum urate as a predictor of clinical and radiographic progression in Parkinson's disease Arch Neurol 65 716 723 10.1001/archneur.2008.65.6.nct70003 18413464 (Pubitemid 351831449)
14. P Klivenyi RJ Ferrante RT Matthews MB Bogdanov AM Klein OA Andreassen G Mueller M Wermer R Kaddurah-Daouk MF Beal 1999 Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis Nat Med 5 347 350 10.1038/6568 1:CAS:528:DyaK1MXhsVSrtr4%3D 10086395 (Pubitemid 29124375)
15. RT Matthews RJ Ferrante P Klivenyi L Yang AM Klein G Mueller R Kaddurah-Daouk MF Beal 1999 Creatine and cyclocreatine attenuate MPTP neurotoxicity Exp Neurol 157 142 149 10.1006/exnr.1999.7049 1:CAS:528: DyaK1MXis1Klurk%3D 10222117 (Pubitemid 29226877)
16. OA Andreassen A Dedeoglu RJ Ferrante BG Jenkins KL Ferrante M Thomas A Friedlich SE Browne G Schilling DR Borchelt SM Hersch CA Ross MF Beal 2001 Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease Neurobiol Dis 8 479 491 10.1006/nbdi.2001.0406 1:STN:280:DC%2BD3Mzps1GgsA%3D%3D 11447996 (Pubitemid 32566138)
17. P Klivenyi NY Calingasan A Starkov IG Stavrovskaya BS Kristal L Yang B Wieringa MF Beal 2004 Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase Neurobiol Dis 15 610 617 10.1016/j.nbd.2003.12.014 1:CAS:528:DC%2BD2cXivVKmsrs%3D 15056469 (Pubitemid 38429976)
18. JM Shefner ME Cudkowicz D Schoenfeld T Conrad J Taft M Chilton L Urbinelli M Qureshi H Zhang A Pestronk J Caress P Donofrio E Sorenson W Bradley C Lomen-Hoerth E Pioro K Rezania M Ross R Pascuzzi T Heiman-Patterson R Tandan H Mitsumoto J Rothstein T Smith-Palmer D MacDonald D Burke NEALS Consortium 2004 A clinical trial of creatine in ALS Neurology 63 1656 1661 1:STN:280: DC%2BD2crmt1egtA%3D%3D 15534251
19. SJ Tabrizi AM Blamire DN Manners B Rajagopalan P Styles AH Schapira TT Warner 2005 High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study Neurology 64 1655 1656 10.1212/01.WNL.0000160388.96242.77 1:CAS:528:DC%2BD2MXjsVCjsbY%3D 15883340 (Pubitemid 40617715)
20. NINDS NET-PD Investigators 2006 A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease: 18-month results Neurology 66 664 671 10.1212/01.wnl.0000201252.57661.e1 (Pubitemid 43739819)
21. JW Miller J Selhub MR Nadeau CA Thomas RG Feldman PA Wolf 2003 Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status Neurology 60 1125 1129 1:STN:280:DC%2BD3s7msFShsw%3D%3D 12682318
22. J Sauer JB Mason SW Choi 2009 Too much folate: a risk factor for cancer and cardiovascular disease? Curr Opin Clin Nutr Metab Care 12 30 36 10.1097/MCO.0b013e32831cec62 1:CAS:528:DC%2BD1cXhsVKntLjK 19057184
23. JM Savola M Hill M Engstrom H Merivuori S Wurster SG McGuire SH Fox AR Crossman JM Brotchie 2003 Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease Mov Disord 18 872 883 10.1002/mds.10464 12889076 (Pubitemid 37021161)
24. Y Sato M Kikuyama K Oizumi 1997 High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease Neurology 49 1273 1278 1:STN:280:DyaK1c%2FjvFWktA%3D%3D 9371907
25. ML Evatt MR Delong N Khazai A Rosen S Triche V Tangpricha 2008 Prevalence of vitamin D insufficiency in patients with Parkinson's disease and Alzheimer disease Arch Neurol 65 1348 1352 10.1001/archneur.65.10.1348 18852350
26. CW Shults D Oakes K Kieburtz MF Beal R Haas S Plumb JL Juncos J Nutt I Shoulson J Carter K Kompoliti JS Perlmutter S Reich M Stern RL Watts R Kurlan E Molho M Harrison M Lew 2002 Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson's disease: evidence of slowing of the functional decline Arch Neurol 59 1541 1550 10.1001/archneur.59.10.1541 12374491
27. A Storch WH Jost P Vieregge J Spiegel W Greulich J Durner T Müller A Kupsch H Henningsen WH Oertel G Fuchs W Kuhn P Niklowitz R Koch B Herting H Reichmann German Coenzyme Q(10) Study Group 2007 Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson's disease Arch Neurol 64 938 944 10.1001/archneur.64.7.nct60005 17502459 (Pubitemid 47047992)
28. KE Lyons R Pahwa 2006 Efficacy and tolerability of levetiracetam in patients with levodopa-induced dyskinesia Clin Neuropharmacol 29 148 153 10.1097/01.WNF.0000220814.48360.F4 1:CAS:528:DC%2BD28XlsFeisro%3D 16772814 (Pubitemid 44503893)
29. TA Zesiewicz KL Sullivan JL Maldonado WO Tatum RA Hauser 2005 Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease Mov Disord 20 1205 1209 10.1002/mds.20563 15954135 (Pubitemid 41632212)
30. P Jenner A Mori R Hauser M Morelli BB Fredholm JF Chen 2009 Adenosine, adenosine A(2A) antagonists, and Parkinson's disease Parkinsonism Relat Disord 15 406 413 10.1016/j.parkreldis.2008.12.006 1:STN:280:DC%2BD1MvksVWnsg%3D%3D 19446490
31. F Stocchi L Vacca P Grassini MF De Pandis G Battaglia C Cattaneo RG Fariello 2006 Symptom relief in Parkinson's disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition Neurology 67 7 Suppl 2 S24 12 1:CAS:528:DC%2BD28XhtVeqsLfE 17030737
32. J Dutoit C Coetzee T Grant I Shoulson L Rajachandran R Tschopp K Sprenger S Stankovic 2009 Safety, tolerability, efficacy and pharmacokinetics in phase 2 study of aplindore in patients with early stage of Parkinson's disease Movement Dis Suppl.1 S263
33. L Pollak Y Dobronevsky T Prohorov S Bahunker JM Rabey 2007 Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state J Neural Transm Suppl 72 145 148 10.1007/978-3-211-73574-9-17 1:CAS:528:DC%2BD2sXhsVKns7nO 17982887
34. D Devos P Krystkowiak F Clement K Dujardin O Cottencin N Waucquier K Ajebbar B Thielemans M Kroumova A Duhamel A Destée R Bordet L Defebvre 2007 Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease J Neurol Neurosurg Psychiatry 78 470 475 10.1136/jnnp.2006.100016 1:STN:280:DC%2BD2s3itlWjsA%3D%3D 17098845 (Pubitemid 46662893)
35. E Auriel JM Hausdorff T Herman ES Simon N Giladi 2006 Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study Clin Neuropharmacol 29 15 17 10.1097/00002826-200601000- 00005 1:CAS:528:DC%2BD28XitVWmtL8%3D 16518128 (Pubitemid 44378605)
36. JG Nutt JH Carter NE Carlson 2007 Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial Arch Neurol 64 319 323 10.1001/archneur.64.3.319 17353373 (Pubitemid 46425684)
37. E Auriel JM Hausdorff N Giladi 2009 Methylphenidate for the treatment of and other neurological disorders Clin Neuropharmacol 32 75 81 10.1097/WNF.0b013e318170576c 1:CAS:528:DC%2BD1MXlt1Giu7w%3D 18978488
38. DA Mendonça K Menezes MS Jog 2007 Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial Mov Disord 22 2070 2076 10.1002/mds.21656 17674415
39. DJ Surmeier 2007 Calcium, ageing, and neuronal vulnerability in Parkinson's disease Lancet Neurol 6 933 938 10.1016/S1474-4422(07)70246-6 1:CAS:528:DC%2BD2sXht1Krtr%2FN 17884683 (Pubitemid 47405004)
40. S Schuster E Doudnikoff D Rylander A Berthet I Aubert C Ittrich B Bloch MA Cenci DJ Surmeier B Hengerer E Bezard 2009 Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3, 4-dihydroxyphenylalanine-induced dyskinesia Biol Psychiatry 65 518 526 10.1016/j.biopsych.2008.09.008 1:CAS:528:DC%2BD1MXit1Wku7o%3D 18947822
41. F Stocchi L Fabbri L Vecsei A Krygowska-Wajs PA Monici Preti SA Ruggieri 2007 Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson's disease Clin Neuropharmacol 30 18 24 10.1097/01.WNF.0000236762.77913.C6 1:CAS:528:DC%2BD2sXht1Kkur8%3D 17272966 (Pubitemid 46204314)
42. RA Hodgson R Bertorelli GB Varty JE Lachowicz A Forlani S Fredduzzi ME Cohen-Williams GA Higgins F Impagnatiello E Nicolussi LE Parra C Foster Y Zhai BR Neustadt AW Stamford EM Parker A Reggiani JC Hunter 2009 Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 in rodent models of movement disorders and depression J Pharmacol Exp Ther 330 294 303 10.1124/jpet.108.149617 1:CAS:528:DC%2BD1MXosFeluro%3D 19332567
43. H Németh J Toldi L Vécsei 2006 Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies J Neural Transm Suppl 70 285 304 10.1007/978-3-211-45295-0-45 17017544
44. H Robotka J Toldi L Vecsei 2008 L-kynurenine: metabolism and mechanism of neuroprotection Future Neurol 3 169 188 10.2217/14796708.3.2.169 1:CAS:528:DC%2BD1cXis1Whsrc%3D
45. Vecsei L (2005) Kynurenines in the brain: from experiments to clinics. NOVA, New York
46. T Ogawa WR Matson MF Beal RH Myers ED Bird P Milbury S Saso 1992 Kynurenine pathway abnormalities in Parkinson's disease Neurology 42 1702 1706 1:CAS:528:DyaK3sXnvVGhsQ%3D%3D 1513457
47. A Hadj Tahar L Grégoire A Darré N Bélanger L Meltzer PJ Bédard 2004 Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys Neurobiol Dis 15 171 176 10.1016/j.nbd.2003.10.007 1:CAS:528:DC%2BD2cXhvFSkt7Y%3D 15006686 (Pubitemid 38296747)
48. L Grégoire A Rassoulpour P Guidetti P Samadi PJ Bédard E Izzo R Schwarcz T Di Paolo 2008 Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys Behav Brain Res 186 161 167 10.1016/j.bbr.2007.08.007 17868931 (Pubitemid 350122751)